BNP Paribas Financial Markets Takes $450,000 Position in MiMedx Group, Inc. (NASDAQ:MDXG)

BNP Paribas Financial Markets purchased a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 46,812 shares of the company’s stock, valued at approximately $450,000.

A number of other large investors also recently added to or reduced their stakes in MDXG. SG Americas Securities LLC boosted its position in MiMedx Group by 79.9% in the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company’s stock valued at $802,000 after buying an additional 37,031 shares during the period. Savant Capital LLC acquired a new position in MiMedx Group in the fourth quarter valued at $100,000. Van ECK Associates Corp acquired a new stake in MiMedx Group during the 4th quarter worth approximately $40,000. Palumbo Wealth Management LLC acquired a new position in MiMedx Group in the 4th quarter valued at $171,000. Finally, Principal Financial Group Inc. lifted its position in MiMedx Group by 8.5% in the fourth quarter. Principal Financial Group Inc. now owns 60,226 shares of the company’s stock valued at $579,000 after purchasing an additional 4,731 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the sale, the insider now directly owns 310,836 shares in the company, valued at approximately $2,452,496.04. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 144,018 shares of company stock worth $1,130,312 over the last quarter. 1.70% of the stock is owned by corporate insiders.

MiMedx Group Stock Down 1.3%

Shares of NASDAQ MDXG opened at $6.63 on Monday. The stock has a fifty day moving average price of $7.09 and a 200 day moving average price of $8.17. The company has a market cap of $979.26 million, a P/E ratio of 12.05 and a beta of 1.85. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts’ consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. Research analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th. Wall Street Zen lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, May 9th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.